Innovation

Markers of Prognosis and Therapy in Carcinomas

University of Pittsburgh
posted on 10/30/2007

Cancer cells can evade therapies as a result of defects in the DNA damage response. This invention provides a biomarker for determining which cancers have a specific genetic feature that suggests that they will respond to a specific adjunctive biologic pathway inhibitor to facilitate sensitivity and reduce resistance to radiation therapy and/or chemotherapy.

Suggested Uses

  • Determination of a selective population of cancer patients more likely to respond to radiation and/or chemotherapy with the addition of a CHEK1 inhibitor to their treatment regimen.
  • Use in Head and Neck carcinoma and possibly other tumors such as carcinomas, melanoma and multiple myeloma.

Advantages

  • Biomarker can identify tumors that will responsive to CHEK1 inhibitors
  • Biomarker can be easily detected by several molecular genetic assays
  • Biomarker also may serve as a prognostic marker for head and neck cancers as well as other carcinomas

Innovation Details
 

Detailed Description

This biomarker indicates those cancer patients who should be given CHEK1 inhibitors in conjunction with their radiation and/or chemotherapy to improve treatment outcome.

File Number: 1395 


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Maria Vanegas at University of Pittsburgh for more information.

request more info
People

Case Manager:

Icon_avatar Maria Vanegas

Innovations (45)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

4,076 members 12,312 innovations 109 organizations

Browse

Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

"Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...